{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:31:40Z","timestamp":1787167900941,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","award":["A2018405S"],"award-info":[{"award-number":["A2018405S"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","award":["NIA P30 AG066519"],"award-info":[{"award-number":["NIA P30 AG066519"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp; Dementia"],"published-print":{"date-parts":[[2024,9]]},"abstract":"Abstract<\/jats:title>\n \n INTRODUCTION<\/jats:title>\n Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n We performed a conjoint experiment to compare preferences among 26 patients with mild cognitive impairment for four trial features including designs incorporating active aducanumab\u2010control (vs. placebo), returning tau positron emission tomography (PET) results (vs. no disclosure), remote study partner participation (vs. in person), and increased risk of brain swelling (vs. lower risk). We used a generalized estimating equation to model the utility of factor levels.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n \n Returning tau PET results had the highest utility (est: 0.47; 95% confidence interval [CI]: 0.13, 0.81;\n P<\/jats:italic>\n \u00a0=\u00a00.007); remote study partner participation showed a similar trend (est: 0.29; 95% CI: \u22120.05, 0.63;\n P<\/jats:italic>\n \u00a0=\u00a00.097). Trials with active\u2010controlled design (est: 0.01; 95% CI: \u22120.33, 0.35;\n P<\/jats:italic>\n \u00a0=\u00a00.956) did not demonstrate utility and higher risk of brain swelling had negative utility (est: \u22120.64; 95% CI: \u22120.99, \u22120.30;\n P<\/jats:italic>\n \u00a0<\u00a00.001).\n <\/jats:p>\n <\/jats:sec>\n \n DISCUSSION<\/jats:title>\n Returning additional biomarker results may increase willingness to enroll in early AD trials.<\/jats:p>\n <\/jats:sec>\n \n Highlights<\/jats:title>\n \n \n \n We compared mild cognitive impairment participant preferences for four trial design features.<\/jats:p>\n <\/jats:list-item>\n \n Returning tau positron emission tomography results had the highest utility.<\/jats:p>\n <\/jats:list-item>\n \n Remote study partner participation showed a positive, albeit non\u2010significant, trend.<\/jats:p>\n <\/jats:list-item>\n \n No utility was observed for an active aducanumab\u2010control design.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/alz.14143","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T15:19:54Z","timestamp":1722093594000},"page":"6654-6658","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The utility of recruitment incentives in early Alzheimer's disease trials"],"prefix":"10.1002","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5844-1293","authenticated-orcid":false,"given":"Marina","family":"Ritchie","sequence":"first","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"},{"name":"Department of Neurobiology and Behavior University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Witbracht","sequence":"additional","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunji","family":"Russ","sequence":"additional","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ahmad","family":"Sajjadi","sequence":"additional","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"},{"name":"Department of Neurology University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaby T.","family":"Thai","sequence":"additional","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"},{"name":"Department of Neurology University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tam","sequence":"additional","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"},{"name":"Department of Medicine University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Gillen","sequence":"additional","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"},{"name":"Department of Statistics University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Grill","sequence":"additional","affiliation":[{"name":"UC Irvine Institute for Memory Impairments and Neurological Disorders University of California Irvine California USA"},{"name":"Department of Neurobiology and Behavior University of California Irvine California USA"},{"name":"Department of Psychiatry and Human Behavior University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010023\u201001177\u2010x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.1361"},{"key":"e_1_2_9_4_1","volume-title":"FDA Grants Accelerated Approval for Alzheimer's Drug","author":"Food and Drug Administration","year":"2021"},{"key":"e_1_2_9_5_1","volume-title":"FDA Grants Accelerated Approval for Alzheimer's Disease Treatment","author":"Food and Drug Administration","year":"2023"},{"key":"e_1_2_9_6_1","volume-title":"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval","author":"Food and Drug Administration","year":"2023"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11703"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012329"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000336652.05779.ea"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.10"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000591"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2018.05.003"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12152\u2010017\u20109313\u2010z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3126"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2110468"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3854"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010220801"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11704"}],"container-title":["Alzheimer's & Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.14143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T21:06:53Z","timestamp":1759957613000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.14143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/alz.14143"],"URL":"https:\/\/doi.org\/10.1002\/alz.14143","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"2024-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}